Predictive value of nalidixic acid resistance for detecting salmonellae with decreased ciprofloxacin susceptibility

International Journal of Antimicrobial Agents

Volumn 23, Issue 4, 2004, Pages 332-336

  Albayrak, F ^a   Cokca, F ^a   Erdem, B ^a   Aysev, A D ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Ciprofloxacin susceptibility; Nalidixic acid resistance; Salmonellae

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; DIFFUSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SALMONELLA; SALMONELLA CHOLERAESUIS; SALMONELLA ENTERITIDIS; SALMONELLA HADAR; SALMONELLA IRUMU; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; SCREENING; SENSITIVITY AND SPECIFICITY;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FECES; HUMANS; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; PREDICTIVE VALUE OF TESTS; SALMONELLA; SALMONELLA INFECTIONS; SENSITIVITY AND SPECIFICITY; SEROTYPING;

EID: 1842688866     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.014     Document Type: Article

References (29)

1. Miller S, Hohmann E, Pegues D. Salmonella species (including Salmonella typhi). In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. Churchill: Livingstone; 2000. p. 2344-61.
2. Okun M., Erdem B., Akata F., Tatman M., Gerceker D., Yaǧci S.et al. Antibiotic resistance patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur. J. Clin. Microbiol. Infect. Dis. 20:2001;206-209.
3. Buttler T, Kaye D. Typhoid fever and Salmonella infections other than typhoid fever. In: Andreoli T, Bennett JC, Carpenter CJ, Plum F, Smith LH, editors. Cecil textbook of internal medicine. W.B. Saunders Company; 2000. p. 1681-5.
4. Reid T.M.S. The treatment of non-typhoidal salmonellosis. J. Antimicrob. Chemother. 29:1992;4-8.
5. Giraud E., Brisabois A.B., Martel J.L., Chalus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob. Agents Chemother. 43:1999;2131-2137.
6. Piddock L.J., Griggs D.J., Hall M.C., Jin Y.F. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob. Agents Chemother. 37:1993;662-666.
7. Wain J., Hoa N.T., Chinh N.T., Vinh H., Everett M.J., Diep T.S.et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25(6):1997;1404-1410.
8. Vahaboǧlu H., Hall L.M., Mulazimoglu L., Dodlanli S., Yildirim I., Livermore D.M. Resistance to extended-spectrum cephalosporins, caused by PER-1 beta lactamase, in Salmonella typhimurium from İstanbul, Turkey. J. Med. Microbiol. 43:1995;294-299.
9. Aysev D., Güriz H., Erdem B. Drug resistance of Salmonella strains isolated from community infections in Ankara, Turkey, 1993-1999. Scand. J. Infect. Dis. 33:2001;420-422.
10. Murdoch D.A., Banatvaia N., Bone A., Shoismatulloev B.I., Ward L.R., Threlfall E.J.et al. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet. 351:1998;339.
11. Vasallo F.J., Martin Rabadan P., Alacala L., Garcia Lechuz J.M., Rodriguez M., Bouza E. Failure of ciprofloxacin therapy for invasive non-typhoidal Salmonellosis. Clin. Infect. Dis. 26:1998;535-536.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 6th edition. Approved Standard. NCCLS document M2-A6. Pennsylvania, USA; 1997.
13. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th edition. Approved Standard. NCCLS document M7-A4. Pennsylvania, USA; 1997.
14. Herikstad H., Hayes P., Mokhtar M., Fracaro M.L., Threlfall E.J., Angulo F.J. Emerging quinolone resistant Salmonella in the United States. Emerg. Infect. Dis. 3:1997;371-372.
15. Piddock L.J.V., Ricci V., McLaren I., Griggs D.J. Role of mutation in the gyrA and parC genes of nalidixic acid resistant Salmonella serotypes isolated from animals in the United Kingdom. J. Antimicrob. Chemother. 41:1998;635-641.
16. Gilbert RJ, Humhrey TJ. Food-borne bacterial gastroenteritis. In: Collier L, Balows A, Sussman M, editors. Microbiology and microbial infections. Arnold 1998;539-65.
17. Olsen S.J., Bishop R., Brenner F. The changing epidemiology of Salmonella: trends in serotypes isolated from humans in the United States, 1987-1997. J. Infect. Dis. 183:2001;753-761.
18. Threlfall E.J., Frost J.A., Rowe B. Fluoroquinolone resistance in Salmonellas and Campylobacters from humans. Br. Med. J. 318:1999;943-944.
19. Guillermo P., Batriz M., Terasa L., Carmen M., Elisenda M., Ferran N. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob. Agents Chemother. 44:2000;1140-1145.
20. Erdem B. Salmonella serotyped between 1998-2000 years. J. Infect. 15:2001;137-140.
21. Ruiz J., Castro D., Goni P., Santamaria J.A., Borrego J.J., Villa J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistance clinical isolates of Salmonella serotype typhimurium. J. Med. Microbiol. 46:1997;623-628.
22. Ridley A., Threlfall E.J. Molecular epidemiology of antibiotic resistance genes in multiresistant epidemic Salmonella typhimurium DT 104. Eurosurveillence. 2:1997;81-83.
23. Threlfall E.J., Ward L.R., Rowe B. Increasing incidence of resistance to trimethoprim and ciprofloxacin in epidemic spectrum of resistance in multiresistant Salmonella typhimurium. Lancet. 347:1996;1053-1054.
24. Hakanen A., Pirkko K., Jalava J., Sijtonen A., Huovinen P. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J. Clin. Micro. 37:1999;3572-3577.
25. Brown J.C., Thomson C.J., Amyes S.G. Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J. Antimicrob. Chemother. 37:1996;351-356.
26. Frost J.A., Kelleher A., Rowe B. Increasing ciprofloxacin resistance in Salmonellas in England and Wales 1991-1994. J. Antimicrob. Chemother. 37:1996;85-91.
27. Willke A., Anlar D., Çokça F. Resistance of Salmonella and Shigella in Turkey. Clin. Microbiol. Infect. 5:1999;588-590.
28. Arman D., Willke A., Tural D. In vitro activity of eight antibiotics against Salmonella and Shigella species. Eur. J. Epidemiol. 10:1994;345-347.
29. Aarestrup F., Wiuff C., Molbak K., Threlfall E.J. Is it time to change fluoroquinolone breakpoints for Salmonella spp. Antimicrob. Agents Chemother. 47:2003;827-829.